Pfenex Inc. (NYSEMKT:PFNX) insider Patricia Lady sold 2,000 shares of the business’s stock in a transaction dated Monday, November 21st. The shares were sold at an average price of $9.87, for a total value of $19,740.00. Following the completion of the transaction, the insider now directly owns 4,800 shares of the company’s stock, valued at approximately $47,376. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Pfenex Inc. (NYSEMKT:PFNX) traded up 4.52% during mid-day trading on Wednesday, hitting $9.94. The stock had a trading volume of 22,783 shares. Pfenex Inc. has a 52 week low of $5.78 and a 52 week high of $16.15. The company’s 50 day moving average price is $8.94 and its 200 day moving average price is $8.30. The firm has a market cap of $232.77 million, a PE ratio of 31.16 and a beta of 4.65.

Pfenex (NYSEMKT:PFNX) last issued its earnings results on Wednesday, November 9th. The company reported $1.46 EPS for the quarter, topping the consensus estimate of ($0.56) by $2.02. The company earned $48.82 million during the quarter, compared to the consensus estimate of $3.18 million. During the same quarter in the prior year, the business earned ($0.33) EPS. The firm’s revenue for the quarter was up 2269.9% compared to the same quarter last year. Analysts anticipate that Pfenex Inc. will post $0.05 earnings per share for the current year.

Insider Buying and Selling by Quarter for Pfenex (NYSEMKT:PFNX)

Hedge funds and other institutional investors have recently modified their holdings of the company. Franklin Resources Inc. increased its position in shares of Pfenex by 7.3% in the second quarter. Franklin Resources Inc. now owns 3,926,133 shares of the company’s stock valued at $32,862,000 after buying an additional 266,805 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Pfenex by 2.5% in the second quarter. Vanguard Group Inc. now owns 558,624 shares of the company’s stock valued at $4,676,000 after buying an additional 13,502 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Pfenex by 6.2% in the third quarter. BlackRock Fund Advisors now owns 501,682 shares of the company’s stock valued at $4,490,000 after buying an additional 29,507 shares in the last quarter. Sanders Morris Harris Inc. increased its position in shares of Pfenex by 3.0% in the third quarter. Sanders Morris Harris Inc. now owns 372,628 shares of the company’s stock valued at $3,335,000 after buying an additional 10,971 shares in the last quarter. Finally, BlackRock Institutional Trust Company N.A. increased its position in shares of Pfenex by 3.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 354,482 shares of the company’s stock valued at $2,967,000 after buying an additional 11,968 shares in the last quarter.

Several brokerages have commented on PFNX. Mizuho lowered their target price on Pfenex from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Tuesday, August 9th. TheStreet upgraded Pfenex from a “sell” rating to a “hold” rating in a report on Monday, November 14th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $16.00.

WARNING: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/23/pfenex-inc-pfnx-insider-patricia-lady-sells-2000-shares-of-stock.html.

About Pfenex

Pfenex Inc is a clinical-stage biotechnology company. The Company is engaged in the development of biosimilar and therapeutic equivalent products to branded therapeutics and other high-value and difficult-to-manufacture proteins. Its lead product candidate is PF582, a biosimilar candidate to Lucentis (ranibizumab).

Receive News & Stock Ratings for Pfenex Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfenex Inc. and related stocks with our FREE daily email newsletter.